Zeng Q, Li N, Pan X-F, Chen L, Pan A. Clinical management and treatment of obesity in China. Lancet Diabetes Endocrinol 2021; 9: 393–405—In this Series paper, the sixth and seventh sentence of the second paragraph in the “Lifestyle interventions for obesity in China should have read” section should have read “Participants in the intervention group had lost an average of 1·6 kg in bodyweight after 6 months, whereas the control group had gained an average of 0·2 kg (p<0·0001).60 Improvements were also noted in waist circumference (p<0·0001), body fat percentage (p=0·0003), systolic blood pressure (p=0·01), and diastolic blood pressure (p=0·0004) in the intervention group compared with the control group.” And a Chinese translation of this Series paper has now been added as an appendix. These corrections have been made to the online version as of June 16, 2021.

Article InfoPublication HistoryIdentification

DOI: https://doi.org/10.1016/S2213-8587(21)00148-0

Copyright

© 2021 Elsevier Ltd. All rights reserved.

ScienceDirectAccess this article on ScienceDirect Linked ArticlesClinical management and treatment of obesity in China

China has one of the largest populations with obesity in the world, and obesity has become a major challenge for the country's health-care system. Current guidelines for obesity management are not adequately supported by evidence from clinical studies in Chinese populations. Effective lifestyle interventions suitable for Chinese populations are scarce, insufficient weight-loss medications have been approved by regulatory bodies, and there is low acceptance of non-lifestyle interventions (ie, medications and surgery) among both health-care providers and the general public.

Full-Text PDF